Generic legislation of new psychoactive drugs

  title={Generic legislation of new psychoactive drugs},
  author={Jan G.C. van Amsterdam and David J. Nutt and Wim van den Brink},
  journal={Journal of Psychopharmacology},
  pages={317 - 324}
New psychoactive drugs (NPDs, new psychoactive substances) enter the market all the time. However, it takes several months to ban these NPDs and immediate action is generally not possible. Several European countries and drug enforcement officers insist on a faster procedure to ban NPDs. Introduction of generic legislation, in which clusters of psychotropic drugs are banned in advance, has been mentioned as a possible solution. Here we discuss the pros and cons of such an approach. First… Expand
Worldwide legislative challenges related to psychoactive drugs
The discovery of a “new” psychoactive substance is a relatively exceptional event, while the regulatory response usually involved the assessment of risks to public health and inclusion of the novelExpand
Legislative Measures’ Impact on the New Psychoactive Substances Market
While much has been learned about the impact of various government interventions in the markets for traditionally illicit drugs, the recreational drug markets that operate in a legal gray area areExpand
Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill.
It is appropriate at this time for other governments to assess more fully the nature of the NPS problem, and the potential control approaches. Expand
Emerging drugs in Europe
In the last few years, there has been a rapid increase in the number of NPS launched on the European drugs market and some of these new substances has been detected through surveys/questionnaires, studies in drug samples and biological fluids, and case reports and NPS-induced fatalities. Expand
New Psychoactive Substances: The Regulatory Experience and Assessment of Options
Advances in chemistry, technology, and globalization have contributed to the rapid development and diffusion of NPS (Novel Psychoactive Substances), creating perhaps the most serious challenge to theExpand
The Recent Legal Approach to New Psycho-Active Substances Regulationin Israel: Does it Work?
Background: New Psychoactive Substances (NPS), rapidly spreading on the global drug market have become a major concern in different Countries. The drug control systems did not allow a prompt andExpand
Assessing the 'added value' of European policy on new psychoactive substances.
  • Caroline Chatwin
  • Political Science, Medicine
  • The International journal on drug policy
  • 2017
It is found that, while the new proposal on NPS is more efficient, it is not necessarily more effective, and that there is a disappointing focus on legal frameworks at the expense of research and harm reduction. Expand
Mechanisms and Methods for Placing New Psychoactive Substances under Control
The article deals with the international and national mechanisms used to place new psychoactive substances under control. The authors provide an overview of the systems in use in the United NationsExpand
The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations.
A systems-based prevention approach is proposed that develops existing responses, is multilevel and life course informed in character, and emphasises commonalities between NPS and other legal and illegal drug use. Expand
Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: Experiences from the STRIDA project
The STRIDA project provided a good overview of the current drug situation in Sweden and demonstrated a widespread use and rapid turnover of many different psychoactive substances. Expand


Legal responses to new psychoactive substances in Europe,Issue 34, Summer 2010.
This paper starts from the premise that, when a new psychoactive substance appears on the licit/illicit market in a country in Europe, legislators need to choose whether to bring it under control ofExpand
Controlling new drugs under marketing regulations.
Every EU country should have existing laws for protecting public health that can be applied swiftly yet proportionately to new drugs appearing on the open market with minimum political involvement, and the key is the speed, not the weight, of response. Expand
'Legal highs' an inappropriate term for 'Novel Psychoactive Drugs' in drug prevention and scientific debate.
The necessity of reflecting and posibly reconsidering the use of term ‘legal highs’ in the field of drug revention and research is highlighted, as it refers to two ambiguous and undened characteristics of these products. Expand
Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery
  • D. Nutt
  • Medicine, Psychology
  • Therapeutic advances in psychopharmacology
  • 2011
Last year saw the banning of several new synthetic stimulant drugs and many of their analogues, but it now seems that mephedrone was probably one of the least harmful stimulants, being less potent than most alternatives. Expand
Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies.
  • S. Ross
  • Medicine
  • The Psychiatric clinics of North America
  • 2012
Serotonergic hallucinogen-assisted psychotherapy treatment paradigms for SUDs represent a potential paradigmatic shift within the field of psychiatry and would truly constitute a novel psychopharmacologic-psychosocial treatment paradigm to treat addictive disorders. Expand
Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition
Significant changes in British recreational drug use were seen throughout 2009, with the emergence and rapid growth in the availability and use of substituted cathinones or ‘M‐Cats’ (most notablyExpand
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders, because of the adequate therapeutic window of CBD. Expand
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded toExpand
European Monitoring Centre for Drugs and Drug Addiction
The EMCDDA Programme 2, 'Analysis of responses', set out to identify how social reintegration is understood in each Member State and to map the availability of social reIntegration facilities in Member States according to these national perceptions. Expand
Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis
The findings suggest that CBD has potential as a treatment for cannabis dependence and the acute modulation of the incentive salience of drug cues by CBD may possibly generalize to a treatment to other addictive disorders. Expand